Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Roberto Valente

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6785-2326; OpenAlex author ID A5033287955. Sources: OpenAlex.

Their work

Papers
23 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
87
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 5 papers · 2018: 1 paper · 2019: 5 papers · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 23

  1. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  2. Endoscopic workup in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000777↗
  3. Surgical resection for pancreatic ductal adenocarcinoma with liver metastasis: is this the beginning of a new era? Last author DOI 10.21037/hbsn-24-603↗
  4. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  5. Author Correction: Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cance… Co-author DOI 10.1038/s41598-022-08527-z↗
  6. Metabolic Characterization of Plasma and Cyst Fluid from Cystic Precursors to Pancreatic Cancer Patients Reveal Metabolic Signatures of Bacterial Infection. Co-author DOI 10.1021/acs.jproteome.1c00018↗
  7. Isolation of pancreatic microbiota from cystic precursors of pancreatic cancer with intracellular growth and DNA damaging properties. Co-author DOI 10.1080/19490976.2021.1983101↗
  8. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. Co-author DOI 10.1097/sla.0000000000003301↗
  9. Gynecological and reproductive factors and the risk of pancreatic cancer: A case-control study. Co-author DOI 10.1016/j.pan.2020.07.398↗
  10. Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis. Co-author DOI 10.3390/jcm9113720↗
  11. Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.1016/j.hpb.2018.07.017↗
  12. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature. First author DOI 10.1016/j.pan.2019.05.466↗
  13. Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cancer. Co-author DOI 10.1038/s41598-019-46634-6↗
  14. Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317458↗
  15. Palliative therapy in pancreatic cancer-interventional treatment with stents. Co-author DOI 10.21037/tgh.2019.01.05↗
  16. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  17. Neoadjuvant Treatment in Locally Advanced and Borderline Resectable Pancreatic Cancer vs Primary Resectable Pancreatic Cancer. First author DOI 10.1001/jamasurg.2017.2228↗
  18. Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Co-author DOI 10.1038/s41598-017-13430-z↗
  19. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  20. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients. Co-author DOI 10.3390/ijms18040730↗
  21. Pancreatic Exocrine Insufficiency in Pancreatic Cancer. First author DOI 10.3390/nu9030183↗
  22. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  23. Early onset pancreatic cancer: risk factors, presentation and outcome. Co-author DOI 10.1016/j.pan.2015.01.013↗

Closest collaborators

The 25 strongest of 87 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Urban Arnelo · 9 shared papers, 2017–2024 · strength 1.24
  2. Marco Del Chiaro · 9 shared papers, 2017–2023 · strength 1.00
  3. Asif Halimi · 5 shared papers, 2019–2024 · strength 0.66
  4. Alessandro Coppola · 2 shared papers, 2024 · strength 0.55
  5. Margaret Chen · 5 shared papers, 2019–2022 · strength 0.54
  6. Rogier Aäron Gaiser · 5 shared papers, 2019–2022 · strength 0.54
  7. Carlos Fernández Moro · 4 shared papers, 2019–2022 · strength 0.42
  8. Gabriele Capurso · 5 shared papers, 2015–2020 · strength 0.34
  9. Matthias J. Löhr · 3 shared papers, 2017–2020 · strength 0.31
  10. Lívia Archibugi · 4 shared papers, 2015–2020 · strength 0.29
  11. Sohei Satoi · 2 shared papers, 2019–2023 · strength 0.25
  12. Sofia Svensson Di Giorgio · 1 shared paper, 2024 · strength 0.24
  13. Jun Yoshino · 1 shared paper, 2024 · strength 0.24
  14. Marco Del Chiaro · 2 shared papers, 2019–2022 · strength 0.23
  15. Elena B. Rangelova · 2 shared papers, 2019–2021 · strength 0.23
  16. Alexander Waldthaler · 2 shared papers, 2019–2020 · strength 0.22
  17. Gianfranco Delle Fave · 4 shared papers, 2015–2017 · strength 0.22
  18. Miroslav Vujasinović · 2 shared papers, 2017–2020 · strength 0.19
  19. Matteo Piciucchi · 3 shared papers, 2015–2017 · strength 0.18
  20. Thilo Hackert · 2 shared papers, 2017–2023 · strength 0.17
  21. Patrick Maisonneuve · 2 shared papers, 2017–2020 · strength 0.17
  22. Paolo Marchetti · 2 shared papers, 2015–2020 · strength 0.16
  23. So Yamaki · 1 shared paper, 2023 · strength 0.13
  24. Yoshiaki Murakami · 1 shared paper, 2023 · strength 0.13
  25. Yoo‐Seok Yoon · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.